The estimated Net Worth of William Koschak is at least $3.2 Milione dollars as of 19 August 2021. Mr. Koschak owns over 20,000 units of Calyxt Inc stock worth over $239,400 and over the last 6 years he sold CLXT stock worth over $0. In addition, he makes $2,959,450 as Chief Financial Officer at Calyxt Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Koschak CLXT stock SEC Form 4 insiders trading
William has made over 1 trades of the Calyxt Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of CLXT stock worth $64,200 on 19 August 2021.
The largest trade he's ever made was buying 20,000 units of Calyxt Inc stock on 19 August 2021 worth over $64,200. On average, William trades about 1,333 units every 0 days since 2019. As of 19 August 2021 he still owns at least 38,000 units of Calyxt Inc stock.
You can see the complete history of Mr. Koschak stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
William Koschak biography
William F. Koschak has been appointed as Chief Financial Officer of the company effective as of January 7, 2019. He previously served as the Vice President, Finance of the Brain Therapies division of Medtronic plc, a global medical technology company, from June 2017 through January 2019. During this time, Mr. Koschak also served as interim Vice President and General Manager, Brain Modulation at Medtronic plc from May 2018 through October 2018. Prior to joining Medtronic plc, Mr. Koschak served as the Executive Vice President and Chief Financial Officer of Young America Holdings, LLC, a privately held digital services firm, beginning in December 2014. Earlier in his career, Mr. Koschak held various finance positions at General Mills, where he was employed from May 2005 until December 2014. Prior to General Mills, Mr. Koschak was an audit partner at KPMG LLP. Mr. Koschak has a Bachelor of Arts degree from Augsburg College.
What is the salary of William Koschak?
As the Chief Financial Officer of Calyxt Inc, the total compensation of William Koschak at Calyxt Inc is $2,959,450. There are 1 executives at Calyxt Inc getting paid more, with James Blome having the highest compensation of $4,488,350.
How old is William Koschak?
William Koschak is 51, he's been the Chief Financial Officer of Calyxt Inc since 2019. There are 10 older and 5 younger executives at Calyxt Inc. The oldest executive at Calyxt Inc is Philippe Dumont, 68, who is the Independent Director.
What's William Koschak's mailing address?
William's mailing address filed with the SEC is Mount Ridge Road, Roseville, Ramsey County, Minnesota, 55113-5499, United States.
Insiders trading at Calyxt Inc
Over the last 7 years, insiders at Calyxt Inc have traded over $2,578,214 worth of Calyxt Inc stock and bought 116,475 units worth $1,447,167 . The most active insiders traders include Kimberly K. Nelson, Daniel F Voytas e Yves J Ribeill. On average, Calyxt Inc executives and independent directors trade stock every 23 days with the average trade being worth of $35,853. The most recent stock trade was executed by Yves J Ribeill on 19 September 2022, trading 30,000 units of CLXT stock currently worth $7,200.
What does Calyxt Inc's logo look like?
Complete history of Mr. Koschak stock trades at Calyxt Inc
Calyxt Inc executives and stock owners
Calyxt Inc executives and other stock owners filed with the SEC include:
-
James Blome,
Chief Executive Officer, Director -
William Koschak,
Chief Financial Officer -
Debra Frimerman,
General Counsel -
Kimberly Nelson,
Independent Director -
William F. Koschak,
Chief Financial Officer -
Dr. Travis J. Frey Ph.D.,
Chief Technology Officer -
Daniel Voytas,
Chief Scientific Officer -
Philippe Dumont,
Independent Director -
Yves Ribeill,
Chairman of the Board -
Christopher Neugent,
Independent Director -
Anna Kozicz-Stankiewicz,
Independent Director -
Jonathan Fassberg,
Independent Director -
Chris Tyson,
IR Contact Officer -
Laurent Arthaud,
Director -
Bobby Williams,
Director - Gene Editing -
Vince Restucci,
Vice President of Agronomy Services -
Sarah Reiter,
Vice President - Business Development -
Travis Frey,
Chief Technology Officer -
Keith Blanks,
Senior Vice President of Sales and Marketing -
Gerry Nuovo,
Sr. VP of Bus. Devel. -
Dr. Stephen M. Bravo,
Chief Medical Officer -
Trina Lundblad,
Director of Communications -
Debra H. Frimerman,
Gen. Counsel & Corp. Sec. -
Dr. Daniel F. Voytas Ph.D.,
Founder, Chief Science Officer & Chair of Scientific Advisory Board -
Michael Allen Carr,
Pres, CEO & Director -
Michael A. Carr,
President and CEO -
Manoj Sahoo,
Chief Commercial Officer -
Alain Godard,
Director -
Bryan W.J. Corkal,
Chief Financial Officer -
Michel Arbadji,
Director of Business Developme -
Federico A. Tripodi,
Chief Executive Officer -
Glenn R Bowers,
Vice President of Breeding -
S.A. Cellectis,
10% owner